Typhaneoside Flavonoid for Uric Acid Reduction and Kidney Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperuricemia, such as allopurinol and febuxostat, have adverse reactions and can exacerbate kidney injury, while there is a lack of effective drugs for uric acid-lowering and hyperuricemic kidney protection.
Innovation Solution
The use of typhaneoside, a flavonoid compound, in a pharmaceutical formulation with a medically acceptable carrier to lower uric acid levels and protect kidneys from hyperuricemic injury, with a molecular formula of C34H42O20 and various dosage forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If xanthine oxidase inhibitors (allopurinol, febuxostat) are used to lower uric acid, then uric acid synthesis is inhibited, but severe adverse reactions occur including skin damage, cardiovascular risks, and hepatotoxicity
Solution Approach 1:
The patent extracts and utilizes a specific flavonoid compound (typhaneoside) from traditional Chinese medicine with molecular formula C34H42O20, isolating its dual mechanism of action that simultaneously promotes uric acid excretion and provides kidney protection, thereby avoiding the severe adverse reactions associated with conventional xanthine oxidase inhibitors
Solution Approach 2:
The flavonoid compound acts as an intermediary substance that mediates between uric acid excretion and kidney protection functions. It promotes uric acid excretion through renal mechanisms while simultaneously providing renoprotective effects, serving as a bridge that achieves uric acid lowering without the harmful side effects of current medications
2Quantity of substance
If allopurinol is used for hyperuricemia treatment, then uric acid synthesis is inhibited, but kidney injury is exacerbated
Solution Approach 1:
The patent converts the potential harm of hyperuricemia-induced kidney injury into a beneficial outcome by using the flavonoid compound that not only lowers uric acid levels but actively protects kidney function. The compound transforms the pathological process into a therapeutic opportunity where uric acid excretion is promoted while kidney tissues are protected from damage
Solution Approach 2:
The invention employs a composite pharmaceutical formulation containing the flavonoid compound (C34H42O20) combined with medically acceptable carriers, creating a composite medication that integrates multiple therapeutic functions: uric acid promotion of excretion and kidney protection, thereby achieving reliable kidney protection while effectively managing hyperuricemia
3Quantity of substance
If current uric acid-lowering drugs are used, then blood uric acid levels are reduced, but renoprotective effects are absent or kidney injury is worsened
Solution Approach 1:
The flavonoid compound exhibits multi-functionality by simultaneously performing multiple therapeutic roles: it promotes uric acid excretion through renal mechanisms, protects kidney tissues from hyperuricemic injury, and provides anti-inflammatory effects. This universal compound addresses multiple aspects of hyperuricemia management in a single medication
Data Source
AI summary
The present disclosure herein belongs to the field of biomedicine, and discloses an application of typhaneoside in preparation of a medicine for uric acid-lowering and/or hyperuricemic kidney injury, wherein the typhaneoside is the sole active ingredient in the preparation of a medicine for uric acid-lowering and/or hyperuricemic kidney injury. The typhaneoside being able to significantly reduce the blood uric acid level, at the same time, the typhaneoside is able to improve hyperuricemic kidney injury by lowering the uric acid deposition in the kidneys. As a drug for anti-hyperuricemia and improving hyperuricemic kidney injury, typhaneoside shows significant application prospects and is widely used in the market.